Einzeltreffer — DigiBib

CRTAC1, one of the pyroptosis-related genes, has been identified as a protective factor in certain kinds of cancer, such as gastric adenocarcinoma and bladder cancer. The study aimed to investigate the role of CRTAC1 in lung adenocarcinoma (LUAD). LUAD datasets were obtained from Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA), pyroptosis-related genes from GeneCard. Limma package used to find differentially expressed genes (DEGs), least absolute shrinkage and selection operator (LASSO) regression and weighted genes co-expression network analysis (WGCNA) to identify CRTAC1 as hub gene. CRTAC1 expression was confirmed in a real-world cohort using quantitative polymerase chain reaction (qPCR) and Western Blot (WB) analyses. Cellular experiments were conducted to investigate CRTAC1's potential oncogenic mechanisms. CRTAC1 mRNA expression was significantly lower in LUAD tissues (p < 0.05) and showed high accuracy in diagnosing LUAD. Reduced CRTAC1 expression was associated with a poor prognosis. Higher CRTAC1 expression correlated with increased immune cell infiltration. Individuals with high CRTAC1 expression showed increased drug sensitivity. Additionally, qPCR and WB analyses showed that CRTAC1 expression was lower in tumor tissue compared to adjacent normal tissue at both the RNA and protein levels. Upregulation of CRTAC1 significantly inhibited LUAD cell proliferation, invasion, and migration in cellular experiments. CRTAC1 has the potential to serve as a diagnostic and prognostic biomarker in LUAD.

Titel:	CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma.
Autor/in / Beteiligte Person:	Tan, L ; Zhang, H ; Ding, Y ; Huang, Y ; Sun, D
Link:	Full Text Finder (Volltext)
Zeitschrift:	Scientific reports, Jg. 14 (2024-05-16), Heft 1, S. 11223
Veröffentlichung:	London : Nature Publishing Group, copyright 2011-, 2024
Medientyp:	academicJournal
ISSN:	2045-2322 (electronic)
DOI:	10.1038/s41598-024-61804-x
Schlagwort:	Humans Prognosis Male Female Cell Proliferation genetics Cell Line, Tumor Middle Aged Gene Expression Profiling Cell Movement genetics Biomarkers, Tumor genetics Biomarkers, Tumor metabolism Adenocarcinoma of Lung genetics Adenocarcinoma of Lung diagnosis Adenocarcinoma of Lung pathology Adenocarcinoma of Lung mortality Adenocarcinoma of Lung metabolism Lung Neoplasms genetics Lung Neoplasms diagnosis Lung Neoplasms pathology Gene Expression Regulation, Neoplastic
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Sci Rep] 2024 May 16; Vol. 14 (1), pp. 11223. <i>Date of Electronic Publication: </i>2024 May 16. MeSH Terms: Biomarkers, Tumor* / genetics ; Biomarkers, Tumor* / metabolism ; Adenocarcinoma of Lung* / genetics ; Adenocarcinoma of Lung* / diagnosis ; Adenocarcinoma of Lung* / pathology ; Adenocarcinoma of Lung* / mortality ; Adenocarcinoma of Lung* / metabolism ; Lung Neoplasms* / genetics ; Lung Neoplasms* / diagnosis ; Lung Neoplasms* / pathology ; Gene Expression Regulation, Neoplastic* ; Humans ; Prognosis ; Male ; Female ; Cell Proliferation / genetics ; Cell Line, Tumor ; Middle Aged ; Gene Expression Profiling ; Cell Movement / genetics References: Cell Commun Signal. 2022 Sep 19;20(1):147. (PMID: 36123698) ; J Gastrointest Oncol. 2022 Oct;13(5):2219-2233. (PMID: 36388651) ; Curr Opin Oncol. 2020 Jan;32(1):63-67. (PMID: 31599771) ; Cell Death Discov. 2021 Jun 25;7(1):161. (PMID: 34226539) ; Carcinogenesis. 2012 Nov;33(11):2126-34. (PMID: 22843550) ; Methods Mol Biol. 2023;2644:349-359. (PMID: 37142933) ; Cell Res. 2015 Dec;25(12):1285-98. (PMID: 26611636) ; Matrix Biol. 2007 Jan;26(1):30-41. (PMID: 17074475) ; J Thorac Dis. 2022 Mar;14(3):654-667. (PMID: 35399245) ; J Exp Clin Cancer Res. 2020 Sep 5;39(1):179. (PMID: 32891166) ; Thorac Cancer. 2020 Aug;11(8):2130-2136. (PMID: 32500560) ; Cell Prolif. 2019 Mar;52(2):e12563. (PMID: 30525268) ; Int J Cancer. 2010 May 1;126(9):2199-210. (PMID: 19626602) ; Cell Death Dis. 2021 Apr 6;12(4):352. (PMID: 33824285) ; Front Oncol. 2022 Sep 29;12:1006477. (PMID: 36249034) ; J Cell Mol Med. 2021 May 31;:. (PMID: 34060213) ; Oncoimmunology. 2021 Jan 11;10(1):1860586. (PMID: 33520406) ; Eur J Cancer. 2023 May;185:40-52. (PMID: 36963351) ; J Oncol. 2022 Jul 27;2022:6905588. (PMID: 35938142) ; Front Immunol. 2022 Jul 06;13:844142. (PMID: 35874717) ; PeerJ. 2020 Jan 03;8:e8312. (PMID: 31921517) ; Clin Exp Med. 2018 Feb;18(1):1-14. (PMID: 28752221) ; J Cell Physiol. 2019 Jun;234(6):8509-8521. (PMID: 30520029) ; Nat Rev Immunol. 2010 Apr;10(4):236-47. (PMID: 20224569) ; Hum Genomics. 2020 May 6;14(1):15. (PMID: 32375881) ; Trends Cell Biol. 2015 Oct;25(10):592-600. (PMID: 26410405) ; Front Genet. 2023 Apr 03;14:1160915. (PMID: 37077542) ; Front Genet. 2022 Jun 20;13:891301. (PMID: 35795208) ; Cell Mol Immunol. 2019 Jan;16(1):6-18. (PMID: 29628498) ; Annu Rev Pathol. 2022 Jan 24;17:295-321. (PMID: 34736341) ; Front Cell Neurosci. 2017 Mar 09;11:63. (PMID: 28337127) ; Nat Commun. 2021 Nov 11;12(1):6500. (PMID: 34764257) ; Autoimmun Rev. 2018 Jul;17(7):694-702. (PMID: 29729449) ; Adv Drug Deliv Rev. 2015 Jan;81:34-52. (PMID: 25252098) ; Bioengineered. 2021 Dec;12(2):9377-9389. (PMID: 34818994) ; Front Oncol. 2022 Jun 30;12:881860. (PMID: 35847844) ; Lancet. 2017 Jan 21;389(10066):299-311. (PMID: 27574741) ; Onco Targets Ther. 2019 Sep 06;12:7329-7336. (PMID: 31564915) ; Front Oncol. 2020 Aug 12;10:1344. (PMID: 32903414) ; Med Clin North Am. 2019 May;103(3):463-473. (PMID: 30955514) ; PLoS One. 2012;7(12):e53817. (PMID: 23285300) ; Front Immunol. 2020 Jun 30;11:1218. (PMID: 32714316) ; Cancer Res. 2023 Aug 15;83(16):2690-2703. (PMID: 37249584) ; Cell Death Dis. 2023 Aug 26;14(8):563. (PMID: 37633993) ; J Thorac Dis. 2020 Aug;12(8):4398-4410. (PMID: 32944353) ; Theranostics. 2018 Sep 09;8(17):4649-4663. (PMID: 30279729) ; Nat Rev Cancer. 2006 Nov;6(11):857-66. (PMID: 17060945) ; Int Immunopharmacol. 2020 Sep;86:106744. (PMID: 32623229) ; Biochem Biophys Res Commun. 2018 Jan 1;495(1):1418-1425. (PMID: 29183726) ; Mol Biol Rep. 2022 Nov;49(11):10875-10883. (PMID: 35931874) Contributed Indexing: Keywords: CRTAC1; Diagnosis; LUAD; Prognosis; Pyroptosis Entry Date(s): Date Created: 20240516 Date Completed: 20240516 Latest Revision: 20240519 Update Code: 20240519 PubMed Central ID: PMC11099150

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma.